Research progress of immune checkpoint inhibitors in the treatment of EGFR-TKIs-resistant NSCLC
- VernacularTitle:免疫检查点抑制剂治疗EGFR-TKIs耐药NSCLC的研究进展
- Author:
Yixuan ZHU
1
,
2
;
Yang WANG
2
;
Tongmin WANG
2
Author Information
1. College of Pharmacy，Dali University，Yunnan Dali 671000，China
2. Dept. of Gastrointestinal and Metabolic Surgery for Weight Loss，the First People’s Hospital of Yunnan Province，Kunming 650100，China
- Publication Type:Journal Article
- Keywords:
immune checkpoint inhibitors;
non-small cell lung cancer;
EGFR-TKIs;
drug resistance
- From:
China Pharmacy
2025;36(2):239-244
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） are targeted drugs for the treatment of advanced non-small cell lung cancer （NSCLC）， but long-term use inevitably leads to drug resistance. Resistance to EGFR-TKIs can alter the tumor microenvironment， and patients with NSCLC resistant to EGFR-TKIs can regain the benefits of immune checkpoint inhibitors （ICIs）， but the changes in the tumor microenvironment are complex and the efficacy is unclear. This article reviews the clinical studies of ICIs in the treatment of EGFR-TKIs-resistant NSCLC， and finds that for patients with EGFR-TKIs-resistant NSCLC， the efficacy of ICIs as a single agent is unclear， and other relevant biomarkers need to be found to screen the beneficiary population. ICIs+EGFR-TKIs have potential toxicity and are not recommended for clinical use. There is controversy about the efficacy of ICIs+chemotherapy， and it is recommended to use it cautiously in clinical practice. ICIs+anti-vascular endothelial growth factor （VEGF） drug therapy has a synergistic effect， but may increase the incidence of adverse events. ICIs+chemotherapy+anti- VEGF drug have a synergistic effect and the incidence of adverse events is similar to that of chemotherapy. New ICIs such as lymphocyte activating gene 3 inhibitors are still in the clinical research stage or preclinical research stage， but they may be a new promising treatment.
